gatifloxacin has been researched along with Meningitis, Pneumococcal in 2 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Meningitis, Pneumococcal: An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the cerebrospinal fluid (CSF) pharmacodynamics of a new fluoroquinolone, gatifloxacin (AM-1155), in experimental pneumococcal meningitis." | 3.70 | Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. ( Friedland, IR; Ghaffar, F; Jafri, HS; Lutsar, I; McCoig, CC; McCracken, GH; Ng, W; Wubbel, L, 1998) |
| " Bactericidal activity of gatifloxacin was correlated with the area under the time-concentration curve-to-MBC ratio; maximal activity was achieved when gatifloxacin concentrations exceeded the MBC for the entire dosing interval." | 2.41 | Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis. ( McCracken, GH, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lutsar, I | 1 |
| Friedland, IR | 1 |
| Wubbel, L | 1 |
| McCoig, CC | 1 |
| Jafri, HS | 1 |
| Ng, W | 1 |
| Ghaffar, F | 1 |
| McCracken, GH | 2 |
1 review available for gatifloxacin and Meningitis, Pneumococcal
| Article | Year |
|---|---|
Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Child; Disease Models, Animal; Drug Administr | 2000 |
1 other study available for gatifloxacin and Meningitis, Pneumococcal
| Article | Year |
|---|---|
Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Male; Me | 1998 |